Back to Orbis Allan Gray Ltd Orbis Allan Gray Ltd

CRSPCRSP
7 quarters

Position history for Orbis Allan Gray LtdOrbis Allan Gray Ltd's holdings in CRISPR THERAPEUTICS AG

Yes. Orbis Allan Gray holds 5,449,161 shares of CRSP (Crispr Therapeutics), worth $297.2M, as of its Q2 2026 13F filing. It reduced the position by 656,850 shares (-10.8%) from Q1 2026. Orbis Allan Gray has held CRSP since Q4 2024, across 7 quarterly 13F filings. CRSP is 1.0% of Orbis Allan Gray's reported 13F portfolio.

Current Value

$297.2M

Current Shares

5.4M

Total Value Change

+$239.1M

Total Shares Change

+4M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
5.4M
-10.8%
$297.2M1.0%$54.54
0
2026-Q1
Increased
6.1M
+2.6%
$290.5M1.2%$47.57
50
2025-Q4
Increased
6M
+19.4%
$312M1.3%$52.44
58
2025-Q3
Increased
5M
+80.2%
$322.9M1.4%$64.81
75
2025-Q2
Increased
2.8M
+76.9%
$134.5M0.7%$48.64
65
2025-Q1
Increased
1.6M
+5.9%
$53.2M0.3%$34.03
37
2024-Q4
New
1.5M
-
$58.1M0.3%$39.36
49

Other major holders of CRSP: ARK Investment Management LLC, Capital International Investors

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used